Investors Crushin' on Rare Diseases

CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in

CNBC | February 14, 2012

Tags:. .seema. .moody. .pharmaceutical. .expire. .patents